Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acute myeloid leukemia: 2014 Update on risk‐stratification and management
Elihu H. Estey
American Journal of Hematology (2014) Vol. 89, Iss. 11, pp. 1063-1081
Open Access | Times Cited: 145

Showing 1-25 of 145 citing articles:

‘Acute myeloid leukemia: a comprehensive review and 2016 update’
Ivan de Kouchkovsky, Maher Abdul‐Hay
Blood Cancer Journal (2016) Vol. 6, Iss. 7, pp. e441-e441
Open Access | Times Cited: 1146
Hematopoietic stem cell transplantation for patients with AML in first complete remission
Jan J. Cornelissen, Didier Blaise
Blood (2015) Vol. 127, Iss. 1, pp. 62-70
Open Access | Times Cited: 291
T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
Yaxian Kong, Liuluan Zhu, Todd D. Schell, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 12, pp. 3057-3066
Open Access | Times Cited: 263
Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse
Manoj Garg, Yasunobu Nagata, Deepika Kanojia, et al.
Blood (2015) Vol. 126, Iss. 22, pp. 2491-2501
Open Access | Times Cited: 197
Frontline treatment of acute myeloid leukemia in adults
Gevorg Tamamyan, Tapan M. Kadia, Farhad Ravandi, et al.
Critical Reviews in Oncology/Hematology (2016) Vol. 110, pp. 20-34
Open Access | Times Cited: 130
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
Julia Etchin, Alla Berezovskaya, Amy Saur Conway, et al.
Leukemia (2016) Vol. 31, Iss. 1, pp. 143-150
Open Access | Times Cited: 110
Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities
Xueyan Chen, Brent L. Wood
Blood Reviews (2016) Vol. 31, Iss. 2, pp. 63-75
Closed Access | Times Cited: 86
A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220
Panpan Hou, Chao Wu, Yuchen Wang, et al.
Cancer Research (2017) Vol. 77, Iss. 16, pp. 4402-4413
Open Access | Times Cited: 82
Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms
Annette K. Brenner, Ina Nepstad, Øystein Bruserud
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 77
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice
Julia Etchin, Joan Montero, Alla Berezovskaya, et al.
Leukemia (2015) Vol. 30, Iss. 1
Open Access | Times Cited: 74
Targeting novel signaling pathways for resistant acute myeloid leukemia
Kathleen M. Sakamoto, Steven Grant, Diana Saleiro, et al.
Molecular Genetics and Metabolism (2014) Vol. 114, Iss. 3, pp. 397-402
Open Access | Times Cited: 67
New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia
Razan Mohty, Rama El Hamed, Éolia Brissot, et al.
Haematologica (2023) Vol. 108, Iss. 2, pp. 321-341
Open Access | Times Cited: 21
Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis
Molly Gallogly, Hillard M. Lazarus, Brenda Cooper
Therapeutic Advances in Hematology (2017) Vol. 8, Iss. 9, pp. 245-261
Open Access | Times Cited: 61
Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia
Peter Herhaus, Stefan Habringer, Kathrin Philipp‐Abbrederis, et al.
Haematologica (2016) Vol. 101, Iss. 8, pp. 932-940
Open Access | Times Cited: 60
Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity
Olivia Campagne, Audrey Delmas, Sylvain Fouliard, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 11, pp. 2631-2641
Open Access | Times Cited: 55
Eomes+T-betlow CD8+ T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia
Bei Jia, Chenchen Zhao, Kevin Rakszawski, et al.
Cancer Research (2019) Vol. 79, Iss. 7, pp. 1635-1645
Open Access | Times Cited: 53
Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia
Tibor Kovacsovics, Alice S. Mims, Mohamed E. Salama, et al.
Blood Advances (2018) Vol. 2, Iss. 4, pp. 381-389
Open Access | Times Cited: 52
Association of Leukemia Cutis With Survival in Acute Myeloid Leukemia
Cynthia X. Wang, Iskra Pusic, Milan J. Anadkat
JAMA Dermatology (2019) Vol. 155, Iss. 7, pp. 826-826
Open Access | Times Cited: 51
Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects
N-C Gorin, Sebastian Giebel, Myriam Labopin, et al.
Bone Marrow Transplantation (2015) Vol. 50, Iss. 12, pp. 1495-1502
Open Access | Times Cited: 50
Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients
Aleksandra Butrym, Justyna Rybka, Dagmara Baczyńska, et al.
Journal of Experimental & Clinical Cancer Research (2015) Vol. 34, Iss. 1
Open Access | Times Cited: 50
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape
Chetasi Talati, Kendra Sweet
Leukemia Research (2018) Vol. 73, pp. 58-66
Open Access | Times Cited: 49
Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death
Abhishek Asthana, Parameswaran Ramakrishnan, Yorleny Vicioso, et al.
Molecular Cancer Therapeutics (2018) Vol. 17, Iss. 10, pp. 2226-2237
Open Access | Times Cited: 47
Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia
Elise Aasebø, Frode S. Berven, Sushma Bartaula-Brevik, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 709-709
Open Access | Times Cited: 46
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors
Daniela Damiani, Mario Tiribelli, Donatella Raspadori, et al.
Oncotarget (2015) Vol. 6, Iss. 30, pp. 30212-30221
Open Access | Times Cited: 42
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
Rajeswaran Mani, Swagata Goswami, Bhavani Gopalakrishnan, et al.
Haematologica (2018) Vol. 103, Iss. 8, pp. 1288-1297
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top